ACTT Med is a potential revolutionary paradigm shift in immune support.
From loss to life.
Our CEO Mike Colton started on the path of developing ACTT Med in 2004 after he lost his 20-year-old son, nearly overnight to meningitidis. To honor him and his memory, Mike made it his mission to search for an alternative therapy that could help the body defend itself against fast replicating pathogens.
Our lab results - to be interpreted in vitro only.
Prostate Cancer
Prostate tumor cell load was reduced by 53.3% in 48 hours. (Human DU-145 cells were used. p value of 0.0001)
Coronavirus
Viral load was reduced by an average of 3.7 fold (71.3%) at 48 hours. (Human Coronavirus OC-43 strain was used.)
Neisseria meningitidis
Neisseria meningitidis load was reduced by an average of 3.3 fold (70.3%) at 24 hours. (P value of 0.003)
What the scientific community is saying:
“I did not expect the device to produce any results. This data is interesting & unexpectedly significant.”
DR. FARHAD IMANI